Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation

Lignende værker

• Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia
  af: Buatois, Vanessa, et al.
  Udgivet: (2018)
• CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
  af: Xavier Chauchet, et al.
  Udgivet: (2022-05-01)
• Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
  af: Dheilly, Elie, et al.
  Udgivet: (2018)
• Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
  af: Dheilly, Elie, et al.
  Udgivet: (2017)
• Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
  af: Eric Hatterer, et al.
  Udgivet: (2020-01-01)